Publications by authors named "D Balakrishna"

Claim this Profile
D
Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1.
Mark Sabat, Daniel W Carney, Gloria Hernandez-Torres, Tony S Gibson, Deepika Balakrishna

J Med Chem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age- And Gender-Based Predisposition Of MMP-9 -1562 C > T Genotype And Allele Frequencies With Serum MMP-9 Levels As Probable Risk Factors In Patients With Coronary Artery Disease.
D Balakrishna, B Sowjanya, M Prasad, R Viswakumar

Indian J Clin Biochem· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to "Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ()-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3-1,2,4-triazol-3-one, by Fragment-Based Drug Design".
Mark Sabat, Douglas R Dougan, Jacques Ermolieff, Petro Halkowycz, Beverly Knight, Deepika Balakrishna

J Med Chem· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ()-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3-1,2,4-triazol-3-one, by Fragment-Based Drug Design.
Mark Sabat, Douglas R Dougan, Beverly Knight, J David Lawson, Nicholas Scorah, Deepika Balakrishna

J Med Chem· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.
Pamela J Farrell, Christopher J Zopf, Huey-Jing Huang, Deepika Balakrishna, Corine Holub

J Pharmacol Exp Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis